2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
January 2016 in “Çağdaş tıp dergisi” Topical 1% pimecrolimus effectively treated alopecia areata.
January 2008 in “Zhonghua linchuang mianyi he biantai fanying zazhi” The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
15 citations
,
June 2004 in “International Journal of Dermatology” Most kidney transplant patients in the study had skin problems, often related to infections, medication side effects, or skin cancer risks.
July 2022 in “Journal of Investigative Dermatology” July 2025 in “Dermatology Reports” Mesenchymal stem cell therapy shows promise for treating certain inflammatory skin diseases, but more research is needed.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
January 2012 in “The Year book of dermatology” A woman developed severe kidney injury from using simvastatin with ciclosporin, highlighting the need for careful monitoring when combining these drugs.
August 1994 in “Journal of dermatological science” Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
1 citations
,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
97 citations
,
January 2020 in “Advances in chronic kidney disease” Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
3 citations
,
April 2017 in “Zahedan Journal of Research in Medical Sciences” Almost all kidney transplant patients had complications from immunosuppressive therapy, with excessive hair growth being the most common.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
7 citations
,
October 2008 in “Arthritis Care & Research” Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
1 citations
,
January 1987 in “Veterinary Dermatology” Topical 0.1% tacrolimus improved a rare ear condition in cats.
18 citations
,
July 2018 in “Journal of Cosmetic Dermatology” Calcipotriol plus betamethasone with microneedling works better than tacrolimus for treating vitiligo.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
6 citations
,
September 2021 in “Medical Journal of Cell Biology” Mesenchymal stem cells and their secretome may offer a safe and effective treatment for systemic lupus erythematosus.